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Cell adhesion is of utmost importance in normal development and cellular functions. ICAM-5 (intercellular adhesion molecule-5,
telencephalin, TLN) is a member of the ICAM family of adhesion proteins. As a novel cell adhesion molecule, ICAM-5 shares
many structural similarities with the other members of IgSF, especially the ICAM subgroup; however, ICAM-5 has several unique
propertiescomparedtotheotherICAMs.WithitsnineextracellularIgdomains,ICAM-5isthelargestmemberofICAMsubgroup
identiﬁed so far. Therefore, it is much more complex than the other ICAMs. The expression of ICAM-5 is conﬁned to the
telencephalic neurons of the central nervous system whereas all the other ICAM members are expressed mostly by cells in the
immune and blood systems. The developmental appearance of ICAM-5 parallels the time of dendritic elongation and branching,
and synapse formation in the telencephalon. As a somatodendrite-speciﬁc adhesion molecule, ICAM-5 not only participates in
immune-nervous system interactions, it could also participate in neuronal activity, Dendrites’ targeting signals, and cognition. It
would not be surprising if future investigations reveal more binding partners and other related functions of ICAM-5.
1.Introduction
The immunoglobulin superfamily (IgSF) comprises over 100
members are in vertebrates and most of its members ex-
pressed at the cell surface. Molecules carrying immunoglob-
ulin (Ig) domains are endowed with broad functions which
include cytoskeletal organization, endocytosis, adhesion, mi-
gration, growth control, immune recognition, viral attach-
ment, and tumor progression. The ever growing number of
newly discovered Ig molecules has made this superfamily
increasingly complex.
Intercellular adhesion molecules (ICAMs) are a subset of
the IgSF that bind to leukocyte β2 integrins. There are now
ﬁve members of this family: ICAM-1 has a relatively broad
distribution in diﬀerent tissues, whereas ICAM-2, -3, -4, and
-5showmorerestrictedpatternsoftissueexpression.Theﬁve
ICAMs share many structural and functional features [1].
A 26kb region on human 19p13.2 contains ICAM-1 (MIM
147840), ICAM-4, and ICAM-5 (MIM 601852) genes [2].
Structurally, all ICAMs have lg-like domains; functionally,
most ICAMs participate in immune system interaction.
Notably, ICAM-5/TLN may play important roles both in the
immune and nervous systems.
In this review, the main focus is placed on the structure,
expression, and function analysis of mouse, rabbit, and
human ICAM-5. Here I will discuss the characterizations of
ICAM-5 gene and protein structure and expression as well as
function in the nervous system.
2. Structureof ICAM-5
ICAM-5 is a membrane glycoprotein that was ﬁrst puriﬁed
from the telencephalic regions of the rabbit brain, thus
named ICAM-5 [3]. Since then, the cDNAs of rabbit [4],
mouse [4], and human [5] ICAM-5 have been cloned. The
cDNA cloning reveals that ICAM-5 belongs to the Ig
superfamily, comprising an NH2-terminal signal peptide, a
characteristic extracellular region with nine Ig-like domains,
a single transmembrane region, and a COOH-terminal cy-
toplasmic tail [4, 5]. The overall length of cDNA is about
3.0 Kb, and consists of 11 exons in all mammal species. The
amino acid sequence of diﬀerent species revealed that it is
a type I integral membrane glycoprotein of 130kDa, with a
107kDa polypeptide composed of a signal peptide (26-27
amino acids), a large extracellular region (792–805 amino
acids), a transmembrane region (28 amino acids), and a2 Comparative and Functional Genomics
relatively short cytoplasmic tail (59–64 amino acids) [4–6].
The extracellular portion contains nine tandem repeats of
C2-type Ig domains, rendering a member of the IgSF.
2 . 1 .S tru ctu r eo ft h eM o u seI C A M - 5G en ea n dP r o t ei n . Mouse
ICAM-5 gene is located in the ICAM gene cluster containing
ICAM-1, ICAM-4 and ICAM-5 within 30kb on the mouse
chromosome 9. The nucleotide sequence of the 5 -ﬂanking
region of mouse gene is highly homologous to that of human
and dog orthologs, suggesting the presence of important
regulatory elements for its transcription [6]. The mouse
ICAM-5 is linked to low-density lipoprotein receptor (Ldlr),
ICAM1, and amyloid precursor-like protein 2 (Aplp2). It
contains approximately 3.9kb of the 5 -ﬂanking region,
6.3kb of the gene, and 2.6kb of the 3 -ﬂanking region.
The entire protein-coding sequence was divided into 11
exons. There was a correlation between exon-intron gene
structureandfunctionaldomainsofICAM-5protein.Exon1
included a translation initiation methionine (ATG) followed
by a putative signal peptide. Exons 2–10 were clustered
within 4kb and encoded individual nine Ig-like domains of
the extracellular region. Exon 11 contained both transmem-
brane and cytoplasmic regions of ICAM-5 followed by a
polyadenylation signal (AATAAA) 116bp downstream from
the stop codon (TGA) [4].
Using total ICAM-5-RNA from mouse telencephalon, in
whic hmRN Aisspeciﬁcallye xpr essed[4,7],stronglypositive
signals were detected, located at 92, 94, and 95bp upstream
from the ATG start codon, whereas no speciﬁc signal was
foundwithtotalICAM-5-RNAfrommousecerebellum.This
indicates that nucleotides 92–95bp upstream from the start
codon are potential transcription initiation site of the mouse
ICAM-5 gene.
Of the three potential sites, in particular nucleotides
around adenine, matched a consensus sequence
(YYCAYYYYY) for a strong initiator element [8]. This initi-
ator sequence has been proposed to function as an alter-nate
TFIID-binding site in genes lacking a TATA box [9]. Two
CAAT boxes (−23 to −20) and (−36 to −33) and a binding
site for CAAT/enhancer binding protein (C/EBP) (TKTG-
GWNA) (−47 to −40) [10] were found in the upstream
vicinity of the transcription start site [4]. In mouse ICAM-
5-cDNA, a potential polyadenylation signal (AATAAA) was
found at nucleotides 2910–2915. Analysis of the promoter
region of the mouse ICAM-5 gene revealed a consensus
strong initiator element for TATA-fewer genes, two CAAT
boxes, and numerous putative transcription factor binding
sites. Of note are four E-box (CANNTG) and two N-box
(CACNAG) sequences clustered at positions −949 to −365,
four copies of Nkx-2.5 sites (CWTAATTG and TYAAGTG)
[11], three copies of Sp1 sites (GRGGCRGGGW) [12], two
copies of c-Ets-1 sites (CMGGAWGYN) [13] ,ah e a ts h o c k
factor-2 binding site (HSF2) (GAANNWTCK) [14], an
Oct-1 site (RTAATNA) [15], a GC box (KRGGCGKRRY)
[16], an interleukin 6-induced nuclear factor-binding site
(NF-IL6) (AGTGANGNAA) [17], an Evi-1-binding site
(ACAAGATAA) [18], and a Pbx-1-binding site
(ANCAATCAW) [19] .T h eE -a n dN - b o x e sh a v eb e e ns h o w n
to be binding sites for transcription factors which belong
to the basic helix-loop-helix superfamily, such as MASH-1,
HES-1, -2, -3, -4, -5, MATH-1, -2, and E12/E47 [20, 21]. The
proximal region of mouse chromosome 9 shares regions of
homology with human chromosomes 19p and 11q [20]. The
nucleotide sequence of the 5 -ﬂanking region of mouse gene
is highly homologous to that of human and dog orthologs’,
suggesting the presence of important regulatory elements for
its transcription [6].
All 30 Cys residues (28 in the extracellular region; 2 in
the cytoplasmic region) were completely preserved in mouse
ICAM-5protein[4].ThestructureofICAM-5ismostclosely
related to those of ICAM-1 and -3 with more than 50%
amino acid identity in the distal ﬁve Ig-like domains [4, 5].
The ﬁrst to fourth Ig-like domains of mouse ICAM-5 are
aligned with the corresponding domains of mouse ICAM-1
[22], mouse ICAM-2 [23], and human ICAM-3/R [24, 25].
The ﬁfth to eighth immunoglobulin-like domains of mouse
ICAM-5 protein are aligned with the ﬁfth domain of mouse
ICAM-1 and human ICAM-3/R [4]. The domain I of mouse
ICAM-5 shares 26%–29% amino acid identity with that of
ICAMs. In particular, domains II, III, and IV of mouse
ICAM-5 share 60%, 66%, and 64% amino acid identity
with the corresponding domains of ICAM-3/R, respectively.
Domains V, Vl, VII, and VIII in mouse ICAM-5 protein are
similar to each other, with pairwise identities in the range
of 31%–49%. Although the previous reports on ICAMs
disagree in setting a possible junction between domains IV
a n dV[ 26–28], the repeating structure in domains V–VIII
indicatesthatdomainsIVandVcontain2and4Cysresidues,
respectively. The cytoplasmic sequence of mouse ICAM-5
comprises 59 amino acids [4]. In addition, the cytoplasmic
domain of ICAM-5 contains one and two potential sites for
phosphorylation by protein tyrosine kinases and by casein
kinase II, respectively, (Tyr-868, Ser-875, and Ser-903 in
mouse).
The distal-most Ig-like domain of ICAM-5 contains 4
cysteine residues that are capable of forming two intrado-
main disulﬁde bridges. Similarly spaced cysteine residues in
theNH2-terminalIg-likedomainsareseeninothermembers
oftheIgsuperfamily,suchasICAM-1[26,27],ICAM-2[29],
ICAM-3 [24, 25], LW (ICAM-4) [30–32], and MAdCAM-1
[33]. The NH2-terminal Ig-like domains of ICAM-1, -2, -3,
-4, and ICAM-5 contain characteristic four cysteine residues
thatareconsideredtobeimportantforintegrinbinding[34].
2.2. Structure of the Rabbit ICAM-5 Gene and Protein. A
full-length cDNA of rabbit reverse transcribed from rabbit
hippocampus total ICAM-5 RNA is 3013bp which includes
an open reading frame of 2736 nucleotides beginning at
position 125, terminates at nucleotide 2860 and two mRNA-
destabilizingsequencemotifs(ATTTA)inthe3  untranslated
region [4].
A hydrophobicity proﬁle of the protein revealed that
rabbit ICAM-5 has the typical features observed in type I
integral membrane proteins. A potential initiating Met is
followed by a putative signal sequence [35] with 29 amino
acids. The overall identity of rabbit and mouse ICAM-5Comparative and Functional Genomics 3
is 78% at the nucleotide level and 82% at the amino
acid level [4]. Rabbit ICAM-5 also contains nine tandem
Ig-like domains in its extracellular region with intrachain
disulﬁde bonds typical of Ig-like loops [36]. Domain I of
ICAM-5 protein is unusual for an Ig-like domain: it contains
4 Cys residues with the potential to form two disulﬁde
bridges. In contrast, domains II, III, and IV are highly ho-
mologous to the corresponding domains of ICAM-1 and
-3/R. Domains V–VIII of ICAM-5 are highly conserved four
tandem repeating units, each containing 81–93 amino acids.
These domains are closely related to domain V of ICAM-1
and -3tR. All these domains contain 4 conserved Cys, 3 Pro,
3G l y ,1T r p ,1T y r ,1A l a ,a n d1V a l .T h e s eC y sr e s i d u e s
in domains V–VIII are arranged in a motif diﬀerent from
that found in domain I. Domain IX of ICAM-5 protein has
all the conserved hallmarks of the C2-SET Ig-like domain
[36]. Among the nine Ig-like domains of ICAM-5, only
domain IX has a characteristic Trp residue between the 2 Cys
residues. This type of domain is observed in a number of
IgSF molecules expressed in the nervous system [37, 38]. The
sequence of positions 30–821 is predominantly hydrophilic
and is followed by a stretch of 30 hydrophobic residues,
which is characteristic of a membrane-spanning domain.
The cytoplasmic region at the C-terminus of the protein is
61 residues in length and this region has little homology
with any ICAM members [4]. Instead, the middle portion
(45 amino acids: residues 859–903) of the rabbit ICAM-5
cytoplasmic domain shows the highest homology with the
N-terminal region of rabbit cardiac troponin-T2 [39]. Both
sequences are highly acidic and contain a Gly-rich motif.
Surprisingly, 10 out of the 11 residues (91%) are identical
in these Gly-rich sequences of motif and troponin-T2.
Among the known IgSF molecules, the cytoplasmic domain
is most similar to the Ng-CAM cytoplasmic domain (1163–
1218), with 39% identity [40]. In addition, the cytoplasmic
domain of ICAM-5 contains one and two potential sites
for phosphorylation by protein tyrosine kinases and by
casein kinase II, respectively (Tyr-861, Ser-868, and Ser-884
in rabbit ICAM-5).The mature protein gives rise to a 883
amino acid polypeptide with an expected molecular weight
of 92,762 and 14 potential Asn-linked glycosylation sites.
Among other superfamily members, it is most similar to
ICAMs 1, 2, and 3/R [24–27].
2.3. Structure of the Human ICAM-5 Gene and Protein.
The human gene was mapped to the human chromosome
19p13.2, where the ICAM-1, -3, and -4 (LW) genes are lo-
cated [5]. Genetically, four of the ﬁve human ICAMs (all
but ICAM-2) are clustered on a region of chromosome
19p13.2 [5, 41, 42]. This clear indication of gene duplication
events argues for the existence of a primordial ICAM,
whose expression pattern and functional signiﬁcance have
expanded as new members have arisen. ICAM-5 has a long
open reading frame of 2,772 nucleotides, a 59-untranslated
region of 65 nucleotides, and a 39-untranslated region of
198 nucleotides, which contains a polyadenylation signal
at 13 nucleotides upstream of the poly (A) tail in. Within
the 39-untranslated region there are ﬁve ATTTA motifs,
which are believed to confer instability to mRNA [43, 44].
There is one potential translation initiation site (ATG, nucle-
otides 66–68) surrounded by the nucleotides well matching
with the Kozak’s consensus sequence [45]. An in-frame
termination codon TAG locates 54 nucleotides up-stream of
the initiator ATG. The human ICAM-5 gene is composed
of 11 exons encoding the signal peptide, each of the nine
extracellular domains, and with a single exon encoding both
thetransmembraneandthecytoplasmicdomains[46].Chen
et al. [47] reported that there exist V301I and T348A poly-
morphisms in the gene. Allele frequencies diﬀered in African
Americans from published frequencies for Europeans. For
instance, the minor allele frequencies in African Americans
for the two ICAM-5 SNPs were both 9.2%, as compared to
34–44% among Germans and Australians. However, there is
disagreement on this issue [48].
The human ICAM-5 is 84 and 85% identical with mouse
and rabbit in amino acid sequence, respectively. The human
ICAM-5 polypeptide contains two hydrophobic segments,
which may serve as a signal peptide (27 residues at the
NH2 terminus) and a transmembrane region (28 residues
near the COOH terminus). Between the two hydrophobic
regions, there is a large extracellular region (805 residues)
with 15 potential N-linked glycosylation sites. A cytoplasmic
region at the carboxyl terminus is 64 residues in length.
The extracellular region of human ICAM-5 comprises nine
tandemly arranged Ig-like domains, rendering it to be a
member of the Ig superfamily [36, 37, 49]. In particular,
the distal eight Ig-like domains are closely related to those
of ICAMs [25, 30]. Total amino acid identity is 50% with
ICAM-1 (domains I–V), 55% with ICAM-3 (domains I–V),
38% with ICAM-2 (domains I and II), and 32% with ICAM-
4 (domains I and II). The highest homology is observed
with the domain II of ICAM-1 and the domains II–IV of
ICAM-3 with more than 64% amino acid identity (Figure 1).
The presence of nine Ig-like domains and the position of all
cysteine residues (28 in the extracellular region and 2 in the
cytoplasmic region) are completely conserved in all the three
species. Twelve N-linked glycosylation sites are conserved in
human, mouse, and rabbit.
3. Expressionof ICAM-5
The expression of ICAM-5 protein is conﬁned to the mam-
maliantelencephalonofthecentralnervoussystem[3,4,50],
whereasalltheotherICAMmembersareexpressedmostlyby
cells in the immune and blood systems, such as lymphocytes
(ICAM-1 and -3), endothelial cells (ICAM-1 and -2),
epithelial cells (ICAM-1), and erythrocytes (ICAM-4) [24,
25, 27, 29, 30]. Within the telencephalon, the expression
of ICAM-5 is restricted to certain types of neurons. For
example, in the adult rabbit olfactory bulb, granule cells,
but not mitral and tufted cells express [51]; in the cat visual
cortex, is absent in neurons within layer IV, which receives
massive aﬀerent input from the thalamus, but is present in
neurons of other cortical layers [52]; in the rat hippocampus,
expression is excluded from GABA- (γ-aminobutyric acid)
energic inhibitory interneurons, but is expressed in nearly4 Comparative and Functional Genomics
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Figure 1: Structural comparison of with ICAM-1, -2, -3, and LW antigen (ICAM-4). A, amino acid sequence alignment of with ICAMs and
LW antigen. The amino acid sequence of human (domains I–V) was aligned with those of ICAM-1 (domains I–V) (8, 9), ICAM-2 (domains
I and II) (10), ICAM-3 (domains I–V) (11, 12), and LW antigen (domains I and II) (13). The open circles denote the highly conserved Cys
residues. The residues conserved in more than three of the ﬁve members (domains I and II) or more than two of the three (domains III–V)
are highlighted. B, proposed model of the domain structure of ICAMs and LW antigen. Amino acid identities between the corresponding Ig-
like domains of ICAMs and LW antigen are shown with Arabic numerals above the Ig-like domains, respectively. Individual Ig-like domains
are numbered I–IX on the top. Extra- and intracellular orientations are indicated by NH2 and COOH on the protein chains, respectively.
Intradomain disulﬁde bonds are represented by SS (Cited from [5]).
all excitatory pyramidal neurons [53]. Northern blot analysis
demonstrated human mRNA of 3.0 kilobase pairs in the
hippocampus; however, no signal was detected in the cere-
bellum [5].
At the subcellular level, ICAM-5 is localized exclusively
on the membrane of ﬁlopodia as well as the membranes
of cell bodies and dendrites but not on axons [6, 53, 54].
On cultured hippocampal neurons, ICAM-5 is expressed in
dendritic growth cones and ﬁlopodia.
In rodents, ICAM-5 is almost absent from embryonic
brain, appears around birth, increases dramatically during
the postnatal weeks, and continues to be expressed at a high
level in the adult brain [4]. Expression of ICAM-5 is devel-
opmentallyregulated,withtheﬁrstappearancearoundbirth,
a drastic increase in a few weeks postnatally, and persistence
of high levels in adult life. Thus, the expression of ICAM-
5 is brain segment-speciﬁc, neuron-speciﬁc, somadendritic
membrane-speciﬁc, and develops mental stage-speciﬁc [3, 4,
50–52].
3.1. Expression of the Mouse ICAM-5 Gene and Protein. In
situ hybridization was performed to determine in detail the
spatial pattern of ICAM-5 expression. A parasagittal plane
of adult mouse brain hybridized with antisense cRNA probeComparative and Functional Genomics 5
displaying that ICAM-5 mRNA was detected exclusively in
telencephalic regions. No particular hybridizing signals were
observed in a parallel control experiment with sense cRNA
probe.Itshowsaboundaryregionbetweenthetelencephalon
(caudate putamen) and the diencephalon (globus pallidus).
Positive signals were seen only in neurons of the caudate
putamen, and not in those of the globus pallidus. The te-
lencephalon-restricted expression of ICAM-5 mRNA is con-
sistent with the immunohistochemical results showing the
expression of its protein. The mRNA was expressed strongly
in granule cells of the dentate gyrus, pyramidal cells of the
hippocampus, granule cells of the olfactory bulb, and neu-
rons in layers II/111 and V/Vl of the cerebral neocortex.
However, little or only weak signals were detected in several
typesoftelencephalicneurons,suchasmitral/tuftedcellsand
periglomerular cells in the olfactory bulb and neurons in
layer IV of the cerebral neocortex. These results indicate that
within the telencephalon, ICAM-5 is expressed in a neuronal
type-speciﬁc manner [4].
3.2. Expression of the Rabbit ICAM-5 Gene and Protein. The
level of ICAM-5 mRNA in rabbit telencephalon is low at
embryonic day 25, elevated dramatically by postnatal day 10,
andremainshighuntiladulthood[4,7].Immunohistochem-
istry has also revealed that the amount of ICAM-5 is small
in the cerebrum of a newborn rabbit. At this stage, ICAM-
5 is hardly detectable in most areas of the neocortex, and
its localization is restricted to phylogenetically older regions
such as the olfactory bulb, piriform cortex, corpus striatum,
cingulate cortex, and hippocampus. After birth (postnatal
day 0–10), the densities and areas of ICAM-5-positive struc-
turesrapidlyincrease[50].Northernblotanalysiswithafull-
length probe of rabbit ICAM-5 cDNA was done to survey
the expression of mRNA during development, in adult brain
regions and peripheral tissues showing that in embryonic
day 25 rabbit telencephalon, a faint signal of transcript was
detected at 3.2kb; at postnatal day 10, the level of mRNA
was dramatically increased, and the level remained high
into adulthood. The expression of transcript was conﬁned
exclusively to telencephalic regions, including the olfactory
bulb ,olfact oryc ort e x,c er ebralneoc ort e x,hippocampus,and
striatum. No hybridizing signal was detected in other brain
segments (diencephalon, mesencephalon, metencephalon,
and myelencephalon) or in the spinal cord. In addition,
transcript was not observed in peripheral tissues such as
the heart, lung, kidney, spleen, intestine, and skeletal muscle
[4].
3.3. Expression of the Human ICAM-5 Gene and Protein.
In the adult human brain, immunoreactivity of ICAM-5
localizedtothetelencephalicgraymatter:thecerebralcortex,
hippocampus, and basal ganglia. The labeling intensity
changed during development, and the time course varied
among regions: the hippocampus showed a rapid increase
in immunoreactivity of ICAM-5 in the late fetal period
and temporal cortex in the early infancy, the cerebral white
matter, as well as the other brain segments such as the thal-
amus, cerebellum, and brainstem, remained negative for at
all the developmental stages [55]. In the cerebrum of a 25-
gestational-week(GW)fetus,therewasnoimmunoreactivity
of ICAM-5. The hippocampus was the ﬁrst structure to show
positivity at 29GW. At 29–33GW, weak staining was noted
in the neuropil of the cornu ammonis (molecular and pyra-
midal layers) and area dentata (molecular layer). At 35GW,
the overall immunoreactivity was comparable to that of an
adult brain. In the molecular layer of the cornu ammonis,
apical dendrites of the pyramidal neurons were intensely
stained. Thereafter, the zone showing maximal staining
moved from the middle to the upper third of the layer [55].
At ﬁrst, labeling was weak and restricted to the cytoplasm
of pyramidal neurons from 35 to 39GW, but thereafter it
became diﬀused and intense in the cortical layers. The stain-
ing was most intense in the molecular (1st) layer, moderate
intheexternal(3rd),andinternalpyramidal(5th)layers,and
leastintense inthe external(2nd) andinternal granular(4th)
layers.
On the western blot of homogenates of the frontal
cortex, ICAM-5 (130kDa) was detectable in the tissues of
three postnatal patients, whereas those of a 30-GW fetus
and a 39-GW neonate contained no detectable amount of
ICAM-5. Among the former, there was no signiﬁcant dif-
ferenceinthecontent.Intheneuropilofthetemporalcortex,
immunoreactivity of ICAM-5 appeared ﬁrst at 2 postnatal
monthsandwasrapidlyincreasedby5months.Theblotthus
demonstrated a sharp increase in the amount of ICAM-5
that occured during the early infancy [55]. In conclusion, the
upregulation of ICAM-5 occurs in human cerebrum around
birth, which is comparable to the previous results in animals
and the suspected roles in constructing neuronal networks
[4, 7, 51, 52].
To compare the development of ICAM-5 with that of
twoothermarkersofdendritic/synapticdevelopment:MAP2
and synaptophysin. The former is a high molecular weight
protein that facilitates intracellular transport, whereas the
latter is a membrane glycoprotein of presynaptic vesicles. In
the human cerebral cortex, MAP2 and synaptophysin are
ﬁrst detectable at 20 and 23GW, respectively, according to
previousdevelopmentalstudies[56–58].Immunoreactivities
for synaptophysin and MAP2 appeared earlier than that for
ICAM-5, being detectable in the 25GW cerebrums. In the
hippocampus and temporal cortex, the neuronal perikarya
was positively stained for synaptophysin at 25GW, and their
dendrites at 32–36GW. The peak level of expression was
reached at 37–40GW. MAP2 staining was noted in the
neuronal perikarya and dendrites at 25GW. The intensity
was increased by 32–36GW, and decreased thereafter [55].
These markers appear prior to 25GW, when ICAM-5 is not
yet detectable. Thus the development of ICAM-5 appeared
to be associated with the late phase of dendritic/synaptic
development. In conclusion, in human cerebrum, ICAM-5
appears in the hippocampus from the 29th gestational week,
and in the temporal cortex from the 35th to 39th ges-
tational weeks, intensiﬁes during the perinatal period, and
persistsintoadulthood.Thus,thedevelopmentalappearance
of ICAM-5 parallels the time of dendritic elongation and
branching, and synapse formation in the telencephalon.6 Comparative and Functional Genomics
4. Function of ICAM-5
4.1. Immunological Activities. Human ICAM-5 binds to the
CD11a/CD18integrin,andthatthebindingregioninICAM-
5 is localized to the ﬁrst ﬁve Ig domains [59]. ICAM-5 D1-Fc
supported the binding of T cells at about 70% of the wild-
type level, which was signiﬁcantly higher than T cell binding
to control human IgG [60]. The binding of T cells to ICAM-
5 D1-D2-Fc was slightly higher than to ICAM-5 D1-Fc. The
binding was almost completely abrogated when the ﬁrst or
the ﬁrst two domains were deleted. The sixth domain of
ICAM-5 supported T cell binding at about 60% of the wild-
type level.
Protein constructs containing the ﬁrst Ig domain of
ICAM-5 were able to support CD11a/CD18 interaction,
while deletion of the ﬁrst domain abolished binding. Mon-
oclonal antibodies reacting with the ﬁrst domain of ICAM-5
also completely blocked the interaction. The soluble ﬁrst
domain of ICAM-5 inhibited the binding of T cells to
immobilizedICAM-5atconcentrationsof50nMandhigher.
Interestingly, the sixth domain of ICAM-5 was also able to
support leukocyte binding, but this binding activity may
not involve leukocyte integrins. To test the involvement
of ICAM-5 in leukocyte-neuron interactions, an assay
using human T cells binding to rat hippocampal neurons
was established. This binding was blocked by monoclonal
antibodies against CD11a/CD18 and ICAM-5 [60]. Thus
ICAM-5 may act as a major adhesion molecule for leukocyte
binding to neurons in the central nervous system.
ICAMs mediate intercellular adhesion events also
through interaction with a common counter receptor leuko-
cyte function-associated antigen-1 (LFA-1) integrin in the
nervous and immune systems, respectively [5, 34, 59]. Thus,
LFA-1 integrin has an intimate relationship with ICAMs
both structurally and functionally. ICAM-5 as a candi-
dateforpostsynapticelementstocontactleukocytefunction-
associated antigen-1 (LFA-1), a major leukocyte integrin
expressed in lymphocytes and microglia, was precisely op-
posed to CD18-positive structures in presynaptic elemente
[61]. ICAM-5 has been shown to bind to LFA-1 [5, 59, 60]
and to regulate the morphology of microglia [62]. In the
central nervous system, LFA-1 is selectively and consti-
tutively expressed by microglia, suggesting that ICAM-5-
LFA-1 binding may mediate cell-cell interactions between
telencephalic neurons and microglia. ICAM-5 induced an
intensive spreading of lamellipodia, causing a rapid change
in microglial morphology. In contrast, ICAM-5 induced no
signiﬁcant change in morphology of neuroblastoma and
ﬁbroblasts. Furthermore, the ICAM-5-induced spreading of
microglia was accompanied by a clustering of LFA-1 on cell
surface membrane [62]. These results provide evidence that
ICAM-5 binding to the surface of microglia transduces sig-
nals into microglia that mediate or accelerate cell spreading
and LFA-1 redistribution, implying that neuronal ICAM-5
may control the state and function of microglia in both
physiological and pathological conditions. Data also suggest
that ICAM-5 plays a critical role in modulating chemokine
production in the CNS [63].
In conditions of brain ischemia [64], epilepsy [65, 66],
and encephalitis [67], the soluble form of ICAM-5/sICAM-5
has been detected in physiologic ﬂuids. Tian et al. [68]ﬁ n d
that the expression of ICAM-5 is not upregulated by the
cytokines tumor necrosis factor (TNF) and interferon-γ
(IFN-γ). Activated T cells promote the cleavage of ICAM-5
from neurons, which results in the formation of the
sICAM-5. Whereas sICAM-1 acts as a costimulatory,
sICAM-5 suppresses the T-cell receptor- (TCR-) mediated
activation of T cells as indicated by the decreased expression
of CD69, CD40L, and CD25 (IL-2R) on T cells, especially
CD45ROLow naive T cells. Moreover, sICAM-5 promotes the
expression of transforming growth factor-β1( T G F - β1) and
IFN-γ,b u tn o tT N F[ 68]. SICAM-5 attenuates the T-cell
receptor-mediated activation of T cells as demonstrated by
the decreased expression of the activation markers CD69,
CD40L, and CD25 (IL-2R). This eﬀect is most clearly seen
in CD45ROLow (naive), and not in CD45ROHigh (memory)
T cells, and is most eﬀective early in priming, but not in
the presence of strong costimulatory signals. Furthermore,
sICAM-5 promotes the mRNA expression of the cytokines
TGF-β1a n dI F N - γ, but not TNF. ICAM-5 can bind to LFA-1
that is expressed on the surface membrane of microglia.
It is also possible that the LFA-1-ICAM-5 binding might
mediate the signal for the activation of microglia. Actually,
ICAM-5 is not involved in the pathological changes in the
cell-to-cell contacts between microglia and pyramidal cell
dendrites [69]. Study of CSF samples of patients with acute
encephalitis and MS showed that sICAM-5 was increased in
encephalitis (320 ± 107ng/mL; n = 25), as compared with
patients with MS (128 ± 10ng/mL; n = 16) and control
subjects without CNS disease (137 ± 6ng/mL;n = 42) [67].
It suggests that sICAM-5 is cleaved from CNS into CSF
during acute encephalitis, and it may mediate leukocyte-
neuron interactions. SICAM-5 release from cerebral neurons
may actively regulate immune responses and leukocyte
adhesion during microbial neuroinvasion in humans during
encephalitis. Importantly, ICAM-5 can be cleaved under
pathological conditions and released into the cerebral-
spinal ﬂuid and blood. Soluble ICAM-5 was detected in
experimental hypoxic-ischemic injury of the brain [64]a n d
encephalitis [67]. The ICAM-5 immunoassay may turn out
to be clinically useful in the diﬀerential diagnosis of brain
diseases [67]. In fact, it attenuates T cell activation, evidently
throughitsinﬂuenceontheexpressionofvariouscellsurface
receptors and cytokines [68]. Moreover, ICAM-5-mediated
neuronal regulation of T cell activation is aimed at a very
speciﬁc early transitional stage, which provides a relevant
mechanism in acute versus chronic neuroinﬂammation.
Thus, ICAM-5 may interfere with the formation and func-
tion of immunological synapses, and strengthen the immune
privilege of the brain. This function may turn out to be
pivotalinthebrain,whereinﬂammationoftenisdeleterious.
4.2.NeuritisOutgrowth-PromotingActivity. Duringdevelop-
ment, ICAM-5 appears in parallel with dendritic elongation
and branching, as well as synaptic formation in the telen-
cephalon [4, 51, 52]. ICAM-5 immunoreactivity appearedComparative and Functional Genomics 7
at 29 gestational weeks (GW), intensiﬁed subsequently, and
persisted into adulthood. In the temporal cortex labeling
was weak and restricted to the cytoplasm of pyramidal
neurons from 35 to 39GW, but thereafter became diﬀuse
and intense in the cortical layers, especially the molecular
layer, by 5 months of postnatal age. The development of
ICAM-5 was late compared to synaptophysin and micro-
tubule-associatedprotein2,suggestingitsinvolvementinthe
functional maturation of neuronal dendrites and synapses
[55]. In agreement, ICAM-5 has been shown to promote
dendritic elongation and branching of hippocampal neu-
rons in vitro [70]. Surface coated ICAM-5-Fc promoted
dendritic outgrowth and arborization of ICAM-5-expressing
hippocampal neurons [70].
ICAM-5-deﬁcient mice exhibited decreased density of
dendritic ﬁlopodia and accelerated maturation of dendritic
spines [71]. ICAM-5 facilitates the formation and main-
tenance of dendritic ﬁlopodia and thereby slows spine
maturation in hippocampal neurons. Tamada et al. [72]
examined neurite outgrowth-promoting activity of ICAM-5
by using a culture of hippocampal cells dissociated from
E16 mouse. After 24h in culture, many neurons extended
neurites on the plates coated with recombinant ICAM-5/Fc
chimeric protein which was composed of the extracellular
region of mouse ICAM-5 and the Fc region of human IgG1.
In contrast, only a few neurons extended neurites on the
control plates without ICAM-5/Fc. The length of neurite
showed nonlinear dose-dependent relationship with the
concentration of ICAM-5/Fc. Since human IgG did not show
any signiﬁcant neurite outgrowth-promoting activity, the
neurite outgrowth on ICAM-5/Fc appears to be caused by
the extracellular region of ICAM-5, but not by the Fc region
of IgG. Although ICAM-1 has a structure closely related to
ICAM-5, only a negligible neurite outgrowth was found on
ICAM-1/Fc even at the highest concentration (100mg/mL).
Neurite outgrowth was greatly reduced when ICAM-5/Fc
substrates were blocked by the incubation with the anti-
ICAM-5 antibody. On the other hand, neurite outgrowth
on laminin substrates was not signiﬁcantly changed by the
incubation with the same antibody. These results conﬁrm
that ICAM-5 has a neurite outgrowth-promoting activity.
In vitro studies also show that ICAM-5 colocalized
with both α-actinin and F-actin and ICAM-5-cytoskeletal
association is involved in neuritic outgrowth [73]. It found
that the ICAM-5/α-actinin interaction is involved in neu-
ritic outgrowth and the ICAM-5857–861 cytoplasmic peptide
induced morphological changes in Paju-ICAM-5 cells. It
indicates that the interaction between ICAM-5 and α-actinin
is mediated through binding of positively charged amino
acids near the transmembrane domain of ICAM-5, and
this interaction may play an important role in neuronal
diﬀerentiation.ICAM-5ismainlylocatedindendriticﬁlopo-
dia and immature thin spines. Soluble ICAM-5 promotes
elongation of dendritic ﬁlopodia from wild-type neurons,
but not from ICAM-5-deﬁcient neurons. ICAM-5 deﬁciency
also causes retraction of thin spine heads in response to
NMDA stimulation [74].
The mechanism of ICAM-5 neurite outgrowth-pro-
moting activity is that ICAM-5 has a homophilic binding
activity [70] and ICAM-5-ERM interaction [75]. On the one
hand, the homophilic adhesion of ICAM-5 mediates in-
duction of dendritic outgrowth [72]. On the other hand,
ICAM-5 cytoplasmic region binds ERM (ezrin/radixin/
moesin)familyproteinsthatlinkmembraneproteinstoactin
cytoskeleton. Besides, ICAM-5 ectodomain can interact with
β(1) integrins, and it can stimulate β(1) integrin-dependent
phosphorylation of coﬁlin, an event that has previously been
linked to MMP-dependent spine maturation [76]. The two
things may lead to activation of signal transduction.
4.3. Dendrites’ Targeting Signals. A full-length ICAM-5 ec-
topically expressed in the Purkinje cells was localized exclu-
sivelytodendritesbutnottoaxons.Adeletionofcytoplasmic
C-terminal 12 amino acids (residues 901–912) or a point
mutation of Phe905 to Ala abrogated the dendrite speciﬁc
targeting with appearance of the truncated and point-
mutated ICAM-5 in both axons and dendrites. The cyto-
plasmic region of ICAM-5 consists of ∼60 amino acids that
are highly conserved across animal species. Furthermore,
an addition of the C-terminal 17 amino acids (residues
896–912) of ICAM-5 to an unrelated molecule (CD8) was
suﬃcientforitsspeciﬁctargetingtodendritesinseveraltypes
of neurons [54]. This result suggests that an open structure
of the ICAM-5 C terminus is important to execute selective
targeting into dendrites. Because the C-terminal region of
ICAM-5 does not contain any canonical dendritic targeting
sequences such as the tyrosine-based motif or the dileucine
motif, this study suggests a novel mechanism of protein
traﬃcking to the dendritic compartment of neurons. The
cytoplasmic region of ICAM-5 contains only one Tyr at 861
and one Phe at 905. The ICAM-5-Y861A mutant showed
dendrite-speciﬁc localization in Purkinje cells, similar to
the full-length ICAM-5. In contrast, the ICAM-5-F905A
mutant was detected both in the dendrites and axons of
Purkinje cells, exhibiting no preference of localization. These
results suggest that Phe905, but not Tyr861, is important
for the dendrite-speciﬁc targeting of ICAM-5. Although
ICAM-5 cytoplasmic region is suﬃcient for dendritic tar-
geting in Purkinje cells, ICAM-5 dendritic targeting signal
does not serve as basolateral targeting signal in polarized
epithelial cells [54]. The important role of ICAM-5-ERM
interaction in the formation of dendritic ﬁlopodia, which
leads to subsequent synaptogenesis and establishment of
functional neural circuitry in the developing brain, also
shows that proteins integrate multiple signals at the cell
cortex. Members of the ERM family link integral plasma-
membrane proteins with underlying actin cytoskeleton,
participate in signal transduction pathways, and mediate
the formation of specialized membrane protrusions such
as microvilli, uropods, and ruﬄes [77, 78]. In cultured
hippocampal neurons, phosphorylated active forms of ERM
proteinsareco-localizedwithICAM-5indendriticﬁlopodia,
whereasα-actinin,anotherbindingpartnerofICAM-5,isco-
localized with ICAM-5 at surface membranes of soma and
dendritic shafts. Expression of ICAM-5 constitutively active
ezrin induces dendritic ﬁlopodia formation, whereas small
interference RNA-mediated knockdown of ERM proteins8 Comparative and Functional Genomics
decreases ﬁlopodia density and accelerates spine maturation
[75]. The results indicate the important role of ICAM-5-
ERM interaction in the formation of dendritic ﬁlopodia,
which leads to signal transduction and subsequent synapto-
genesis and establishment of functional neural circuitry in
the developing brain.
4.4. Association between ICAM-5 and Cognition. In 1998,
Rieckmann et al. conﬁrmed that ICAM-5 as an indicator
for temporal-lobe dysfunction [65]. They found that signif-
icantly higher serum concentrations of sICAM-5 in patients
with acute herpes-simplex encephalitis (122ng/mL) and
established diagnosis of intractable temporal lobe epilepsy
(48ng/mL) than in healthy donor (0.8ng/mL) or patients
with other neurological disease. It is hypothesized that
altered local function of the frontotemporal cortex in local-
ization-related epilepsy might be better predicted by the
biochemical marker ICAM-5 than epilepsy characteristics
such as seizure focus because there is an association be-
tween decreased frontotemporal activation on fMRI, both
detectable ICAM-5 serum levels and levetiracetam use [79].
However,thereisnosigniﬁcantdiﬀerencesobservedbetween
ICAM-5 serum levels in febrile seizures and controls in
children [66].
ICAM-5 immunoreactivity was markedly decreased in
thebrainofAlzheimer’sdisease(AD)patients,particularlyin
the hippocampal formation [80]. In AD brain, the intensity
of neuropil labeling for ICAM-5 was decreased in the
neocortex and more sharply in the hippocampal formation.
In hippocampal CA areas where the neuropil labeling was
completely depleted, a small number of neurons and neu-
ronal processes, particularly the apical dendrite of pyramidal
neurons were stained rather intensely. Nissl staining of
nearbysectionsindicatedthatsuchICAM-5positiveneurons
represented only a few of the remaining neurons in the area.
In a small number of cases, a few neuroﬁbrillary tangles
were stained weakly for ICAM-5. Double immunostaining
forICAM-5andC4drevealedthatC4d-positiveghosttangles
were negative for ICAM-5. The hippocampal structure is
considered to be involved in memory function in which
synaptic plasticity plays an important role. Disruption of
cell-cell interactions, which might be normally maintained
by ICAM-5, would cause functional impairment of the
neuronal networks. The loss of ICAM-5 in the hippocampus
thus might be relevant to dementia in AD patients. It has
yet to be determined whether the reduction of ICAM-5
expression precedes or parallels the neuronal degeneration.
In some ICAM-5 depleted areas a few of the remaining neu-
rons and their dendrites were stained rather intensely. This
might indicate upregulation of ICAM-5 expression by some
surviving neurons, although the reduced neuropil labeling
could also account for the visualization of these neurons.
Blocking of ICAM-5 function using anti-ICAM-5 anti-
body or recombinant soluble ICAM-5 protein caused a
striking suppression of the long-term potentiation (LTP) at
the Schaﬀer collateral-CA1 synapses. The suppression was
observed even when the blocking was initiated immediately
after the tetanic stimuli. These observations suggest a role for
ICAM-5-mediated cell-cell interactions as a key step in the
development of LTP [81].
Independent in vitro and in vivo compelling evidence
showed that ICAM-5 binds to Presenilin 1 and 2 (PS1 and
PS2). Importantly, the interaction was also established at
the endogenous level of expression. It demonstrated that
the interaction is functional and not structural [82]. PS1
deﬁciency results in the abnormal accumulation of ICAM-
5 in intracellular compartment. The ﬁrst transmembrane
domain and carboxyl terminus of PS1 form a binding pocket
with the transmembrane domain of ICAM-5. Remarkably,
APP binds to the same regions via part of its transmembrane
domain encompassing the critical residues mutated in famil-
ial AD. It indicates a spatial dissociation between the binding
site and the proposed catalytic site near the critical aspartates
in PSs. ICAM-5 binds to the membrane spanning region in
presenilins as does APP, and the transmembrane region of
presenilins is often mutated in AD patients [82]. However,
ICAM-5 is not a substrate for γ-secretase cleavage; it displays
a prolonged half-life in PS1−/− hippocampal neurons [83].
ICAM-5 may also be important in the development of AD as
evidenced by its association with presenilins and APP.
5. Conclusion
ICAM-5 is a cell surface glycoprotein whose expression is
conﬁned exclusively within the mammal’s telencephalon [3,
7, 50]. With its nine extracellular Ig domains, ICAM-5 is
the largest member of ICAM subgroup identiﬁed so far.
Therefore it is much more complex than the other ICAMs.
The expression of ICAM-5 is conﬁned to the telencephalic
neurons of the central nervous system, whereas all the other
ICAM members are expressed mostly by cells in the immune
andbloodsystems.ThedevelopmentalappearanceofICAM-
5 parallels the time of dendritic elongation and branching,
and synapse formation in the telencephalon.
ICAM-5 is expressed by subsets of the telencephalic neu-
rons, but not by glial cells. In the neurons, ICAM-5 is lo-
calized to somadendritic membrane, but not to axonal
membrane. In the course of brain development, ICAM-5
ﬁrst appears around birth when the dendritic outgrowth and
branching, spine formation, and synapse formation occur
in the telencephalic regions. Afterwards, ICAM-5 expression
persists even in adulthood. These unique expression patterns
of ICAM-5 in brain segment-, neuronal subsets-, somaden-
dritic membrane-,anddevelopmentalstage-speciﬁcfashions
suggest that ICAM-5 may be a crucial cell surface molecule
for the formation, maintenance, and plasticity of neuronal
networks in the brain [3, 7, 50–52]. Since ICAM-5 is likely to
be involved in the formation and maintenance of neuronal
circuits in the telencephalon [4], it would be interesting to
examinehowICAM-5expressionisalteredinvarioushuman
diseases that aﬀect the intellectual and motor functions.
ICAM-5 is a fascinating molecule. On the one hand it
binds to leukocytes through the integrin and can inactivate
immune cells. Most interestingly, ICAM-5 may also sup-
press immune functions by inhibition of T cell activation.
This inhibitory activity could be important for limitingComparative and Functional Genomics 9
inﬂammatory damage in the brain. On the other hand, the
main physiological functions of ICAM-5 are probably in the
development and maturation of neuronal synapses.
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